vTv Therapeutics (VTVT) EV to CFO (2015 - 2026)

vTv Therapeutics has disclosed EV to CFO across 12 years of filings, most recently posting 33.26 for Q2 2026.

• In Q2 2026, EV to CFO fell 133.63% year-over-year to 33.26; the TTM figure through Jun 2026 stood at 22.7 (down 589.48% YoY), while the FY2025 annual figure was 9.82, down 452.54% from the prior year.
• EV to CFO came in at 33.26 for Q2 2026 at vTv Therapeutics, down from 43.05 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 103.75 in Q2 2022 to a low of 65.83 in Q1 2022.
• Average EV to CFO over 5 years is 7.28, with a median of 11.67 recorded in 2022.
• Year-over-year, EV to CFO slumped 212.54% in 2025 and soared 391.81% in 2026.
• Over 5 years, EV to CFO stood at 10.72 in 2022, then rose by 12.81% to 9.35 in 2023, then climbed by 0.3% to 9.32 in 2024, then tumbled by 187.59% to 26.8 in 2025, then declined by 24.09% to 33.26 in 2026.
• Per Business Quant data, the three most recent EV to CFO figures were 33.26 in Q2 2026, 43.05 in Q1 2026, and 26.8 in Q4 2025.